← 返回

BioCanRx 2022 年癌症免疫治疗峰会论文集

英文原题:BioCanRx Summit for Cancer Immunotherapy 2022 Proceedings.

查看英文原题

BioCanRx Summit for Cancer Immunotherapy 2022 Proceedings.

PubMed 2023/10/23(内容时间) Biochem Cell Biol Q4 · IF 2.2(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

2022年11月19日至21日,BioCanRx在加拿大蒙特利尔举行了疫情后首次线下癌症免疫治疗峰会。会议吸引了患者、学员、研究人员、临床医生和行业专业人士的积极参与,他们齐聚一堂,共同探讨加拿大及全球癌症生物治疗的现状与未来。三场全体会议、三位主旨演讲者、一场激烈的辩论、多场专题讨论,以及海报展示和社交活动,使此次会议令人难忘且富有成效。全体会议讨论了细胞治疗、细胞工程、临床试验的现状以及癌症微生物组的作用,患者的声音在整个会议中受到欢迎并贯穿始终,这在很大程度上得益于学习研究所——BioCanRx旨在将患者伙伴纳入研究的一项倡议。在这篇会议回顾中,我们重点介绍平台报告、主旨演讲者、辩论参与者、专题讨论嘉宾以及患者对本次年会的看法。

展开英文摘要原文

From 19 to 21 November 2022, BioCanRx held its first post-pandemic in-person Summit for Cancer Immunotherapy in Montreal, Canada. The meeting was well attended by patients, trainees, researchers, clinicians, and industry professionals, who came together to discuss the current state and future of biotherapeutics for cancer in Canada and beyond. Three plenaries, three keynote speakers, a lively debate, and panel discussions, together with poster sessions and a social event, made the event memorable and productive.

The current state of cellular therapies, cellular engineering, clinical trials, and the role of the cancer microbiome were discussed in plenary session, and the patient voice was welcomed and present throughout the meeting, in large part due to the Learning Institute, a BioCanRx initiative to include patient partners in research. In this meeting review, we highlight the platform presentations, keynote speakers, debate combatants, panellists, and the patient perspective on the annual meeting.

论文信息

作者
Lee S、Hoskin V、Laumont C、Snelling S、Lindo L、Bird L、Samarkina V、Thurston C
第一作者单位
BioCanRx HQP Summit4CI Working Group, BioCanRx, Ottawa, ON, Canada.Canada
通讯作者单位
Beatrice Hunter Cancer Research Institute, Halifax, NS, Canada.Canada
文献类型
非美国政府资助研究
期刊
Biochemistry and cell biology = Biochimie et biologie cellulaire2024 Feb 1
原文标识
PubMed 37870124 · DOI 10.1139/bcb-2023-0207